Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.
When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look.
For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain.
LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world.
The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe.
A German Federal Court decision has given patent applicants in the life sciences field plenty to think about, as Wolfgang Bublak and Axel Berger explain.
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products.
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit.